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Abstract 
Cellular homeostasis is maintained by the highly organized cooperation of intracellular 
trafficking systems including COPI, COPII, and clathrin complexes. COPI is a coatomer 
protein complex responsible for intracellular protein transport between the endoplasmic 
reticulum and the Golgi apparatus. The importance of such intracellular transport 
mechanisms is underscored by the various disorders caused by mutations in the COPII 
coatomer complex, including skeletal disorders such as cranio-lenticulo-sutural 
dysplasia and osteogenesis imperfecta. In this article, we report a clinically recognizable 
craniofacial disorder characterized by facial dysmorphisms, severe micrognathia, 
rhizomelic shortening, microcephalic dwarfism, and mild developmental delay due to 
loss-of-function heterozygous mutations in ARCN1, which encodes the coatomer 
subunit delta of COPI. ARCN1 mutant cell lines were revealed to have endoplasmic 
reticulum stress, suggesting the involvement of ER stress response in the pathogenesis 
of this disorder. Since ARCN1 deficiency causes defective type 1 collagen transport, 
reduction of collagen secretion represents the likely mechanism underlying the skeletal 
phenotype that characterizes this condition. Our findings demonstrate the importance of 
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COPI-mediated transport in human development, including skeletogenesis and brain 
growth.   
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In eukaryotic cells, secretory and membrane proteins are generally 
synthesized on rough endoplasmic reticulum (ER). Vesicle trafficking is required for the 
correct intracellular transport of these proteins. There are three main intracellular 
protein trafficking systems: COPI, COPII, and clathrin systems1. These transport 
systems are composed of heteromeric proteins forming a lattice-like protein complex 
that coats vesicles for intracellular transport. COPI is a heptameric protein complex 
composed of alpha-COP, beta-COP, beta-prime-COP, gamma-COP, delta-COP, 
epsilon-COP, and zeta-COP subunits1,2. COPI plays an important role in retrograde 
transport from the Golgi apparatus to the ER; however, recent reports also implicate 
COPI in anterograde transport from the ER to Golgi apparatus1–3. For performing highly 
complex cellular functions, intracellular transport achieved by COPI plays cardinal roles 
in cellular homeostasis.  
Disruption of intracellular protein transport in human disease has been 
documented in various genetic disorders. COPII plays major roles in anterograde 
transport from the ER to the Golgi apparatus1, and mutations in COPII components are 
associated with several genetic disorders. These disorders include lipid absorption 
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disorder (MIM: #246700)4, skeletal disorders (such as cranio-lenticulo-sutural dysplasia 
(MIM: #607812)5 and osteogenesis imperfecta (MIM: #616294)6), hematological 
disorders (such as congenital dyserythropoietic anemia type II (MIM: #224100)7 and 
combined deficiency of Factor V and Factor VIII (MIM: #227300, #613625)8,9), Cowden 
syndrome, and thyroid cancer (MIM: #616858)10. However, in contrast to the findings for 
COPII, disease-causing germline mutations in COPI components had not been 
described until lately. Recently, germline mutations of COPA encoding the alpha-COP 
subunit of COPI were described in individuals with hereditary autoimmune-mediated 
lung disease and arthritis, demonstrating that the disruption of COPI transport can 
cause human disease (MIM: #616414)11. Here, we report a clinically recognizable 
genetic disorder that we identified in four individuals; this disorder was characterized by 
facial dysmorphisms, severe micrognathia, rhizomelic shortening, microcephalic 
dwarfism and mild developmental delay caused by germline loss-of-function mutations 
in the Archain 1 (ARCN1), which encodes the coatomer subunit delta of COPI.  
Four individuals with ARCN1 mutations were independently enrolled in our 
study following approval granted by the institutional review boards of The University of 
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Tokyo, Nagano Children’s Hospital, KK Women’s & Children’s Hospital, Singapore, and 
Genetics department of the CHU and University of Liège, Belgium. Informed consent 
was obtained from the guardians of the subjects for genetics and molecular studies. 
Shared clinical features among these four individuals are facial dysmorphisms including 
severe micrognathia, rhizomelic shortening, and microcephalic dwarfism (see 
Supplemental Note, Figure 1, Table I). Subject 1 was referred to the Genetics Clinic of 
Nagano Children’s Hospital at the age of 1 month with the chief complaints of facial 
dysmorphism and intrauterine growth retardation. On physical examination, several 
facial dysmorphisms, including a prominent forehead, downslanted palpebral fissures, 
and severe micrognathia, were noted. In addition, shortening of upper arms and legs, 
and small joint laxity were observed (Figure 1A). A skeletal survey revealed widening of 
the metaphysis and a wide femoral neck (Figure 1B). Subject 2, a boy with 
developmental delay and mild autism, was first seen in the Genetics Clinic, KK 
Women’s & Children’s Hospital, at the age of 1 year and 8 months. Subject 2 had 
micrognathia, scaphocephaly, and hypotelorism, as well as small joint laxity (Figure 1C). 
The clinical history of Subject 3 was partly reported previously by Verloes et al.12. At the 
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age of 25 years, his weight was 98kg, his length was 152cm (-3.5 SD), and his head 
circumference was 50 cm (-5 SD) (Figure 1D). Subject 4, the daughter of Subject 3, 
shared common features with Subject 3, which included intrauterine growth retardation 
followed by postnatal growth failure (length 79.5 cm, -4 SD), microcephaly (head 
circumference 45 cm, -5 SD), and dysmorphic features including microretrognathia, 
hypotelorism, shortening of upper arms and legs, and muscular hypertrophy (Figure 
1E).  
Exome sequencing was performed using genomic DNA extracted from 
peripheral blood cells. Exome sequencing of the probands revealed heterozygous 
ARCN1 loss-of-function mutations in these four probands (Figure 2). The Subject 1’s 
mutation in ARCN1 resulted in a premature stop codon in exon 2 (NM_001655:exon2:c. 
260C>A:p.Ser87*). Exome sequencing of Subject 2 revealed two de novo mutations in 
ARCN1 and SYT1. The ARCN1 mutation was a frameshift variant: 
NM_001655:c.633del; p.Val212Trpfs*15 predicted to create a frameshift in exon 4 
starting at codon Val212 and ending in a stop codon 14 positions downstream (Figure 
2A and Figure S2B). The SYT1 (NM_001135805.1:c.697G>A; p.Asp233Asn) variant is 
Izumi et al.  
 11 
a missense variant that substitutes Aspartic acid at codon 233 with Asparagine (Figure 
S3C). Subjects 3 and 4 were found to have a common ARCN1 mutation, which was 
NM_001655:c.157_158del, leading to p.Ser53Cysfs*39 (Figure S2C). 
In order to evaluate the effect of loss-of-function mutations of ARCN1, 
genome editing was performed using the CRISPR/Cas9 system on the colon 
cancer-derived HCT116 cell line. After the introduction of the ARCN1 mutation into 
these cells, single cell cloning was performed using the limiting dilution technique. The 
gRNA empty vector (ID41824) and hCas9 vector (ID41815) were obtained from 
Addgene (Cambridge, MA, USA). The gRNA target sequence was cloned into the 
gRNA empty vector using Phusion polymerase (M0530S: New England Biolabs) and 
the Gibson assembly system (E5510S: New England Biolabs). The gRNA target 
sequence was CTAAGGCTCTTCTCAAGAG; it is located at exon 2 of ARCN1. Cas9 
and gRNA vectors were transfected into cell lines by electroporation using a Neon 
electroporation system (ThermoFisher Scientific). Genomic DNA was extracted with 
NucleoSpin tissue kits (Macherey-Nagel, Duren, Germany). The presence of the 
ARCN1 mutation was confirmed by Sanger sequencing. A total of 68 clones were 
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screened and 5 clones with ARCN1 mutations were identified. None of the clones 
possessed biallelic loss-of-function mutations of ARCN1, suggesting the importance of 
ARCN1 in maintaining cell viability. Two independent clones possessing 1-bp 
duplication leading to a frameshift that resembled the mutations identified in Subject 1 
(ARCN1: c.262dupA (NM_001655)) were used for subsequent experiments (Figure 
S2D). Analysis using the ExPASy translate tool indicated that this 1-bp duplication leads 
to p.Arg88Lysfs*5. Similar to the mutation found in four individuals with ARCN1 
mutations, this frameshift mutation in the HCT116 cell line likely causes a 
loss-of-function effect, since the mRNA in the case of this 1-bp insertion is predicted to 
undergo nonsense-mediated decay.   
To test if such a truncating mutation caused actual dosage reduction of 
ARCN1, we quantified ARCN1 mRNA using quantitative RT-PCR. Introduction of 
frameshift mutations in exon 2 resulted in reduction in ARCN1 mRNA levels, confirming 
that truncating mutations cause reduction in the levels of ARCN1 transcript (Figure 2B). 
Reduction of ARCN1 mRNA level was also observed in the skin fibroblast samples 
obtained from Subjects 3 and 4 (Figure S4A).   
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In order to test the level of ARCN1, HCT116 cells with and without ARCN1 
mutations were lysed with SDS sample buffer for immunoblotting. Western blotting of 
HCT116 mutant clones demonstrated reduction of ARCN1 compared to the wild type 
clones (Figure 2C). Mild reduction of ARCN1 was also demonstrated in the skin 
fibroblast sample obtained from Subject 4 (Figure S4B). These observations confirmed 
that truncating mutations of ARCN1 cause reduction of ARCN1 mRNA and protein 
levels.  
Given the phenotypic overlap of the probands with ARCN1 mutations and 
collagenopathies such as Stickler syndrome (MIM: #108300), we hypothesized that 
reduction of ARCN1 may have caused intracellular collagen transport defects. To 
evaluate the effect of loss-of-function ARCN1 mutations, siRNA-mediated gene 
knockdown (KD) of ARCN1 was performed on a control skin fibroblast cell line, 
GM02036, since skin fibroblast cell line synthesize type I collagen13,14. The greatest 
reduction in ARCN1 mRNA and ARCN1 protein levels was achieved 4 days after 
ARCN1 KD (Figure 3A and Figure 4A).  
Disruption of intracellular trafficking can cause the accumulation of protein, 
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leading to an ER stress response. When the rate of protein synthesis exceeds the 
capacity of protein folding and protein degradation machinery, the ER stress response 
is induced, which may result in cell death if prolonged15. Therefore, the degree of the ER 
stress response was evaluated in the skin fibroblast cell line after ARCN1 KD. 
Overexpression of stress response genes such as ATF4, DDIT3, and HSPA5 serves as 
a marker of ER stress. Quantitative RT-PCR analysis demonstrated the upregulation of 
all these ER stress response genes after ARCN1 KD (Figure 3B). Therefore, reduction 
in ARCN1 levels triggered the ER stress response. In order to evaluate the 
consequence of ER stress, cells were treated with thapsigargin (2 µM and 5 µM)16 and 
tunicamycin (2 µg/ml and 5 µg/ml)17,18 for 17 hours; then, the total cellular lysates and 
RNA were obtained. Thapsigargin is an inhibitor of the ER Ca2+ATPase and induces ER 
stress, and tunicamycin inhibits the initial step of glycoprotein synthesis in ER and 
induces ER stress. Artificial induction of ER stress by the addition of 
thapsigargin/tunicamycin triggered ARCN1 overexpression, although the amount of 
ARCN1 remained unchanged, suggesting increased ARCN1 turnover during the ER 
stress response (Figure 5A and 5B). Collectively, these results suggest that ARCN1 
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plays a major role in ameliorating the induction of the ER stress response. Evaluation of 
the Subject 4 derived skin fibroblast sample further confirmed the presence of ER stress, 
indicated by the cytosolic accumulation of BiP, which is an ER stress marker (Figure 
S4C and 5). Therefore, reduction in ARCN1 levels triggered the ER stress response. 
Next, the amount of type 1 collagen was evaluated in the control skin 
fibroblasts with ARCN1 KD. Interestingly, ARCN1 KD caused the accumulation of type 
1 collagen in the total cellular lysates (Figure 4A). Type 1 collagen secretion from skin 
fibroblasts was then quantitated by performing trichloroacetic acid (TCA) precipitation of 
culture supernatants. Immunoblotting performed on culture supernatants demonstrated 
the reduction of secreted type 1 collagen in the culture media, suggesting that ARCN1 
reduction caused intracellular accumulation of type 1 collagen due to defective 
intracellular protein transport (Figure 4A). In order to confirm that collagen accumulation 
was a result of defective intracellular transport, 10 µM brefeldin A (BFA), an ER-Golgi 
transport inhibitor, was added to the culture media, and total cellular lysates were 
obtained 23 hours after treatment18. Addition of BFA caused the accumulation of 
intracellular type 1 collagen, similar to what was observed with ARCN1 KD (Figure 4B). 
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Interestingly, BFA treatment reduced the amount of ARCN1 in the cells (Figure 4B). 
Type 1 collagen is encoded by two genes, COL1A1 and COL1A2. The alpha 1 chain of 
type 1 collagen is encoded by COL1A1 and the alpha 2 chain of type 1 collagen is 
encoded by COL1A2. Quantitative RT-PCR demonstrated a slight reduction in COL1A1 
mRNA with ARCN1 KD, while the level of COL1A2 mRNA remained unchanged with 
ARCN1 KD (Figure 4C). Addition of thapsigargin/tunicamycin did not cause 
accumulation of type 1 collagen, suggesting that the ER stress response does not 
cause the collagen transport defect (Figure 5B and Figure S6). These experiments 
indicate that ARCN1 is directly responsible for the intracellular transport of type 1 
collagen and that the collagen transport defect is not secondary to the ER stress 
response. 
In this paper, we report a clinically recognizable genetic disorder 
characterized by facial dysmorphisms, micrognathia, rhizomelic shortening, 
microcephalic dwarfism, and mild intellectual disability due to heterozygous ARCN1 
loss-of-function mutations. We propose the name “ARCN1-related syndrome” to denote 
this condition. The ARCN1 is approximately 30 kb in size and located on chromosome 
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11q23.3 with 10 exons (Figure 2A). Germline mutations of ARCN1 have not been 
previously reported. The Exome Aggregation Consortium (ExAC) website gives a 
probability of loss-of-function intolerance score of 1 to ARCN1, the highest score, given 
the absence of loss-of-function ARCN1 mutations in their cohort19. Therefore, ARCN1 
likely represents a dosage-sensitive gene in humans. To the best of our knowledge, 
germline chromosomal microdeletions spanning the ARCN1 region have not been 
reported in the medical literature. Copy number variations within the ARCN1 locus have 
also not been reported in the Database of Genomic Variants.  
The clinical phenotype of ARCN1-related syndrome includes severe 
micrognathia, microcephalic dwarfism, joint laxity, and mild developmental delay 
(Table1). There is some phenotypic overlap between ARCN1-related syndrome and 
Stickler syndrome such as micrognathia, short stature and joint laxity, although 
neurological, ocular and audiology features differ. Stickler syndrome is caused by 
loss-of-function heterozygous mutations in COL2A1 and other collagen genes20. Given 
the type of the mutations identified in Stickler syndrome, it is presumed that generalized 
reduction in type II collagen production leads to a clinical phenotype of Stickler 
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syndrome such as micrognathia and short stature. This clinical overlap prompted us to 
evaluate the role of ARCN1 in intracellular collagen transport where we demonstrated 
the importance of ARCN1 in this context. Phenotypic resemblance between 
ARCN1-related syndrome and Stickler syndrome could be explained by the reduction in 
collagen secretion from the cells. The importance of ARCN1-associated intracellular 
trafficking has been documented in many biological processes such as immune function 
and influenza virus infection21. The inability to create an ARCN1-null cell line with 
CRISPR/Cas9 underscores the importance of ARCN1 in cell viability. Our findings 
highlight the unexpected importance of COPI transport in skeletogenesis, particularly in 
mandibular bone formation. Previously, similar pathological disease mechanisms 
resulting in skeletal dysplasia were implicated in COPII transport defects such as 
cranio-lenticulo-sutural dysplasia and osteogenesis imperfecta6,22. 
COL2A1 mutations also cause other skeletal dysplasias such as 
achondrogenesis type II/hypochondrogenesis (MIM: #200610), and spondyloepiphyseal 
dysplasia (MIM: #183900). These disorders are collectively termed type II 
collagenopathies23. Many of these conditions are caused by heterozygous mutations in 
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COL2A1. However, the effects of COL2A1 mutations vary in different type II 
collagenopathies. As a result, there is a wide phenotypic spectrum of type II 
collagenopathies. Interestingly, some COL2A1 missense mutations found in type II 
collagenopathies cause abnormal protein folding of type II collagen, leading to the 
intracellular accumulation of mutant collagen, which elicits an ER stress response24. 
Furthermore, the artificial induction of ER stress in chondrocytes causes skeletal 
dysplasia in mice25. Therefore, it is proposed that ER stress itself is involved in the 
pathogenesis of skeletal dysplasia. Hence, in ARCN1-related syndrome, the ER stress 
response may also play a role in the resultant skeletal phenotype. However, our ARCN1 
KD experiments indicate that defective COPI transport could play a direct role in 
intracellular collagen accumulation in ARCN1-related syndrome, rather than the skeletal 
phenotype, which is secondary to ER stress. This finding is consistent with a previous 
report that demonstrated the involvement of COPI in intracellular collagen transport26. In 
order to deepen the understanding of the role that ER stress and COPI transport play in 
skeletogenesis, further studies are warranted. 
 The ER stress response is elicited even during normal embryogenesis27,28. 
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Given the role of ARCN1 in the ER stress response, reduction of ARCN1 likely triggers 
an exaggerated ER stress response, and such an enhanced ER stress response may 
lead to cell death. In addition to the direct influence of ER-Golgi transport defects 
secondary to ARCN1 mutations, such cell death likely contributes to the pleiotropic 
phenotype of ARCN1-related syndrome.  
Mice with a homozygous missense mutation in Arcn1, that is, nur17 mice, 
have been previously created by N-ethyl-N-nitrosourea (ENU) mutagenesis29. The 
nur17 mouse harbors a homozygous missense mutation in exon 10 of Arcn1 and is 
characterized by the presence of dilute coat color, neurological defects, and low body 
weight; however, the skeletal phenotype was not characterized in the original report.  
Mild loss-of-function effects were presumed to mediate disease mechanisms in the 
nur17 mutant mouse. There are several similarities between Arcn1 mutant mice and the 
probands described in these articles, such as low body weight and the neurological 
phenotype including ataxia due to cerebellar degeneration. Interestingly, Subject 4 was 
found to have ataxia and cerebellar atrophy. Hence, nur17 mice may serve as an 
animal model for ARCN1-related syndrome, although skin color and hair abnormalities 
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were not detected in individuals with ARCN1 mutations.   
In addition to the skeletal phenotype, another feature typical of 
ARCN1-related syndrome is mild intellectual disability. There are several lines of 
evidence supporting a role for COPI transport in brain function. First, COPI interacts 
with a subset of RNA molecules, and COPI has been implicated in intracellular RNA 
transport in neuronal cells30. Second, the COPI system is known to transport molecules 
that play major roles in neurotransmitter release such as SNARE proteins31-33. In fact, 
the importance of intracellular trafficking has been well known in neuronal function and 
homeostasis because the abnormalities of intracellular trafficking are linked to the 
pathogenesis of various neurodegenerative disorders such as Alzheimer’s disease34. 
Abnormal ER-Golgi trafficking is demonstrated in Dyggve-Melchior-Clause syndrome 
(MIM: #223800) associated with developmental delay and microcephaly35. Furthermore, 
the presence of ER stress during embryogenesis is well documented in the central 
nervous system, supporting a role for ER stress in brain development27,28. Therefore, 
the findings strongly suggest that COPI is involved in neuronal function. The 
neurological phenotype of the nur17 mouse model further supports the notion that 
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defective ARCN1 function impairs brain function29.  
In addition to intellectual disability, Subject 2 experienced seizures. However, 
it remains to be determined whether the seizures were due to ARCN1 mutations since 
Subject 2 also has a de novo missense SYT1 variant, which was not previously 
reported. SYT1 encodes synaptotagmin1, which plays important roles in synaptic 
vesicle recycling, and there have been two recent reports associating SYT1 mutations 
in a child with a dyskinetic movement disorder and developmental delay, and another 
child with developmental delay, facial dysmorphisms and anomalous EEG patterns36,37 
(Table S3). Therefore, it is possible that the neurological phenotype of Subject 2 is 
partially due to SYT1 mutation. However, since all four probands with ARCN1 mutations 
demonstrated comparable degree of developmental delay/intellectual disability, ARCN1 
mutations likely plays a major role in its neurological phenotype, and ARCN1 is probably 
required for normal brain growth and cognitive development.  
In conclusion, we report a recognizable craniofacial disorder, ARCN1-related 
syndrome, characterized by facial dysmorphisms, micrognathia, rhizomelic shortening, 
microcephalic dwarfism, and mild intellectual disability. Intracellular COPI transport has 
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been implicated in various biological processes and our results strongly indicate the 
importance of COPI transport in skeletogenesis, particularly in mandibular bone 
formation, during embryogenesis.  
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Figure Legends 
Figure 1. Clinical features of the probands with ARCN1 mutations. The guardians of the 
probands provided consent for the publication of their photographs. (A) Physical 
features of Subject 1. Note downslanted palpebral fissures and micrognathia. (B) 
Skeletal survey of Subject 1. Note micrognathia, widening of the metaphysis and a wide 
femoral neck. (C) Facial features of Subject 2. (D) Physical features of Subject 3. Note 
rhizomelic shortening of the limbs. (E) Physical features of Subject 4. Note micrognathia 
and rhizomelic shortening of the limbs.  
Figure 2. Effects of ARCN1 mutation. (A) Structure of ARCN1 and the location of 
ARCN1 mutations identified. Subject 1 has a stop mutation in exon 2 
(NM_001655:exon2:c. 260C>A:p.Ser87*). Subject 2 has a frameshift mutation in exon 
4: NM_001655:c.633del; p.Val212Trpfs*15. Subjects 3 and 4 have a common ARCN1 
mutation in exon 2, NM_001655:c.157_158del, leading to p.Ser53Cysfs*39. (B) mRNA 
level of ARCN1 in HCT116 cell lines with and without ARCN1 mutation. RNA extraction 
was performed with TRIzol reagent (Ambion: 15596-018) and Nucleospin RNA kits 
(Macherey-Nagel, Duren, Germany). The RNA obtained was reverse transcribed with a 
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SuperScript VILO cDNA Synthesis Kit (Invitrogen: 11754-050). The PCR primer sets 
used for quantitative RT-PCR are listed in Table S2. WT: wild type. ARCN1 expression 
level was normalized against GAPDH. Relative ARCN1 expression level to the control 
sample (WT#1) is demonstrated. Data represents mean ± 2 s.d. *** P<0.001, two-tailed 
t test; n=3 technical replicates per group. Three biological replicates for each sample 
demonstrated consistent results. (C) Protein level of ARCN1 in HCT116 cell lines with 
and without ARCN1 mutation. The ARCN1 antibody (ab96725) and histone H3 antibody 
(ab1791) were from Abcam. Three biological replicates for each sample demonstrated 
consistent results. 
Figure 3. ER stress response with the reduction of ARCN1. Skin fibroblast ARCN1 KD 
experiments were performed 3 times, and consistent results were obtained. Two 
different siRNAs (ThermoFisher Scientific: ARCN1HSS100628 (KD1) and 
ARCN1HSS100629 (KD2)) were used in the study. Stealth siRNA was transfected 
using Lipofectamine RNAiMAX reagent (ThermoFisher Scientific) according to the 
manufacturer’s instructions. For ARCN1 KD in skin fibroblasts, two siRNA transfections 
were performed 2 days apart; 4 days after the initial siRNA transfection, RNA and 
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cellular lysates were harvested. (A) ARCN1 mRNA level with ARCN1 knock down. KD: 
knock down. Data represents mean ± 2 s.d, *** P<0.001, two-tailed t test; n=3 technical 
replicates per group. Quantitative PCR was run in triplicates, and mean and standard 
deviation was calculated. ARCN1 expression level was normalized against GAPDH 
expression. Relative gene expression level to the control sample is demonstrated. (B) 
Elevation of ER stress response genes expression upon ARCN1 KD. Data represents 
mean ± 2 s.d. *** P<0.001, two-tailed t test; n=3 technical replicates per group. Gene 
expression level was normalized against GAPDH expression. Relative gene expression 
level to the control sample is demonstrated. 
Figure 4. Collagen transport defects with ARCN1 KD. (A) Reduction of ARCN1 caused 
accumulation of type 1 collagen in total cellular lysates and reduction of type 1 collagen 
secretion. The type 1 collagen antibody (AB758) was from Millipore13. For the 
measurement of culture supernatant type 1 collagen, skin fibroblast cell numbers were 
counted, and equal numbers were plated in culture flasks. The cells were changed to 
serum-free culture media for the final 24 hours, the time point at which the medium was 
harvested. One-tenth the volume of TCA was added and placed on ice for 30 minutes. 
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The samples were centrifuged and precipitates were washed with ethanol. After the 
ethanol wash, the supernatants were dried and the remaining cell pellets were 
dissolved with SDS sample buffer for immunoblotting. TCA precipitation was performed 
4 times, and consistent results were obtained. Two bands of type 1 collagen represent 
the bands for alpha 1 and alpha 2 type 1 collagen. Top larger band represents alpha 1 
type 1 collagen and lower smaller band represents alpha 2 type 1 collagen. (B) 
Brefeldin A (BFA; Sigma-Aldrich B5936)) treatment caused the intracellular 
accumulation of type 1 collagen. 10 uM of BFA was used. DMSO was added for control. 
BFA treatment experiment was performed three times, and consistent results were 
obtained. (C) COL1A1 and COL1A2 expression with ARCN1 KD. Slight reduction of 
COL1A1 expression was elicited with ARCN1 KD, however, the gene expression level 
of COL1A2 remained unchanged. Gene expression level was normalized against 
GAPDH expression. Relative gene expression level to the control sample is 
demonstrated. Data represents mean ± 2 s.d. * P<0.05,*** P<0.001, two-tailed t test; 
n=3 technical replicates per group. 
Figure 5. Artificial induction of ER stress caused ARCN1 mRNA overexpression. (A) 
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Treatment with tunicamycin (Sigma-Aldrich, T7765) and thapsigargin (Sigma-Aldrich, 
T9033) triggered overexpression of ARCN1. ARCN1 expression level was normalized 
against GAPDH expression. Relative gene expression level to the control sample is 
demonstrated. Data represents mean ± 2 s.d. ** P<0.01,*** P<0.001, two-tailed t test; 
n=3 technical replicates per group. (B) The amount of ARCN1 remained unchanged 
with tunicamycin and thapsigargin treatments. The alpha tubulin antibody (T6074) was 
from Sigma-Aldrich. Two different concentrations of tunicamycin treatment (2µg/ml 
(Tuni2) and 5µg/ml (Tuni5)) and thapsigargin treatment (2µM (Tg2) and 5µM (Tg5)) 
were used. DMSO was added for control. Two biological replicates demonstrated the 
consistent results.
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  Subject 1 Subject 2 Subject 3 Subject 4 
IUGR (+) (+) (+) (+) 
Micrognathia (+) (+) (+) (+) 
Cleft palate (-) (-) (-) (+) 
Tracheostomy (+) (+) (-) (-) 
Congenital heart disease VSD (-) (-) (-) 
Cryptorchidism NA (+) (-) NA 
Short stature (+) (+) (+) (+) 
Rhizomelic shortening (+) (-) (+) (+) 
Joint laxity (+) (+) (-) (+) 
Developmental delay (+) (+) (+) (+) 
Autism (-) (+) (-) (-) 
Seizure (-) (+) (-) (-) 
Microcephaly (+) (-) (+) (+) 
ARCN1 mutation p.Ser87* p.Val212Trpfs*15 p.Ser53Cysfs*39 
Table 1: Clinical features of ARCN1-related syndrome. IUGR: intrauterine growth retardation. VSD: ventricular septal defect, 
NA: not applicable. 
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Web Resources 
Database of Genomic Variants (http://dgv.tcag.ca/dgv/app/home) 
Exome Aggregation Consortium (ExAC) website (http://exac.broadinstitute.org/) 
ExPASy translate tool (http://web.expasy.org/translate/) 
GeneMatcher (https://genematcher.org/) 
OMIM: Online Mendelian Inheritance in Man (http://www.omim.org) 
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Supplemental Information 
Supplemental Note: Case Reports  
Subject 1 was referred to the Genetics Clinic of Nagano Children’s Hospital at 
the age of 1 month with the chief complaints of facial dysmorphism and intrauterine 
growth retardation. Severe intrauterine growth retardation was noted during pregnancy. 
Subject 1 was born at 35 weeks gestation and was delivered by normal vaginal delivery. 
Her birth weight was 1100 gm (<3rd centile: -4.18SD), length was 34 cm (<3rd centile: 
-3.72SD), and head circumference was 26 cm (<3rd centile: -3.15SD). At birth, severe 
micrognathia and facial dysmorphism were noted. An echocardiogram revealed the 
presence of a ventricular septal defect. After birth, Subject 1 developed respiratory 
distress, requiring ventilator support. Severe micrognathia was considered to be the 
reason of respiratory distress. Therefore, when she was 6 months old, a tracheostomy 
was performed. The subsequent development of Subject 1 has been slightly delayed; 
she started standing with holding at 10 months and sitting independently at 11 months. 
At 1 year and 10 months, her developmental quotient (DQ) was 65. At the age of 3 
years and 1 month, DQ for motor skills, cognition/adaptation, and language/social skills 
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were 75, 77, and 69, respectively. The overall DQ was 72. At the age of 3 years and 4 
months, she recently met the developmental milestones of approximately 2 years and 6 
months, since she was able to jump up, draw straight lines, and take off her clothes.  
Since birth, she has continued to have short stature and has exhibited failure 
to thrive (Figure S1A). On physical examination, several facial dysmorphisms, including 
a prominent forehead, downslanted palpebral fissures, and severe micrognathia, were 
noted. In addition, shortening of upper arms and legs, and small joint laxity were 
observed (Figure 1A). Beighton score was 5/9. No skin color or hair abnormalities were 
identified. She has not shown any signs of cerebellar ataxia. A skeletal survey revealed 
widening of the metaphysis and a wide femoral neck (Figure 1B). Ophthalmological 
evaluation revealed astigmatism. Audiology evaluation was unremarkable. Brain MRI 
was also unremarkable. Currently, she is 3 years and 4 months old, and her height was 
80.2cm (-4.1SD), weight was 8.8kg (-3SD), and head circumference was 43.4cm 
(-3.2SD). The family history of Subject 1 was unremarkable.   
Subject 2, a boy with developmental delay and mild autism, was first seen in 
the Genetics Clinic, KK Women’s & Children’s Hospital, at the age of 1 year and 8 
Izumi et al. 
 
months. Antenatal scans showed intrauterine growth retardation, micrognathia, and 
possible ambiguous genitalia. Amniocentesis revealed a normal karyotype. Subject 2 
was delivered at 34 weeks gestation via cesarean section and had a birth weight of 
1360 gm (<3rd centile), birth length of 40cm (<3rd centile), and birth head circumference 
of 29cm (10th centile). Postnatally, it was observed that he had severe micrognathia and 
penoscrotal hypospadias and required tracheostomy for respiratory support during 
infancy (Figure S1B). He also developed severe gastroesophageal reflux, requiring 
fundoplication and gastrostomy insertion for the first 3 years of life. The development of 
Subject 2 was slightly delayed; he started walking independently at 13 months and 
climbing stairs at 18 months. He spoke his first words at 17 months. At 7 years of age, 
he has moderate-to-severe language difficulties and currently attends special education 
school. His medical issues include epilepsy and obstructive sleep apnea requiring 
continuous positive airway pressure support at night. An MRI scan of the brain of 
Subject 2 was normal and an electroencephalogram confirmed epileptiform activity. On 
physical examination, it was observed that Subject 2 had micrognathia, scaphocephaly, 
and hypotelorism, as well as small joint laxity (Figure 1C). Beighton score was 2/7. No 
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skin color or hair abnormalities identified. He has not shown any signs of cerebellar 
ataxia. The growth parameters of Subject 2 improved postnatally, and as of 7 years, his 
height is 121 cm, which is in the 10th centile. His mid-parental height is 172.5, which is 
50th centile. Currently he is 10 year and 6 months old, and his current height is 136cm 
(10th percentile) and weight 33.2kg (25th percentile), head circumference was 51cm 
(6th centile (-1.53SD)). His ophthalmological issues include occasional divergent squint 
and myopia. He does not have hearing problems.  
Subject 3 (25 years old) was born at 36 weeks gestation from 
consanguineous parents (cousins): weight 1.450kg (<3rd centile), length 38cm (<3rd 
centile), head circumference 27.6 cm (<3rd centile). Hypotelorism, micrognathia, short 
bowed legs, and high arched palate were noticed at birth. Bilateral posterior cataract 
was diagnosed when he was 6 years old. He had hypertrophic muscular appearance, 
rhizomelic shortness of upper and lower limbs, large hands and feet, micropenis, and 
hypoplastic scrotum. A skeletal survey at 7 years of age demonstrated short femoral 
and humeral diaphysis, thick femoral neck with coxa valga, and advanced wrist bone 
maturation. The Subject 3’s IQ was rated at 65 based on the Wechsler Intelligence 
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Scale for Children (WISC). At the age of 25 years, his weight was 98kg, his length was 
152cm (-3.5 SD), and his head circumference was 50 cm (-5 SD) (Figure 1D). He 
cannot read or write but can be understood. He is an employee in his father’s company 
and has married a woman from another region. 
Subject 4, the daughter of Subject 3, shared common features with Subject 3, 
which included intrauterine growth retardation followed by postnatal growth failure. 
Currently, she is 3 years old, and her height was 79.5 cm (-4 SD), her weight was 
9.650kg (-3SD) and head circumference was 45 cm (-5 SD). She was also found to 
have dysmorphic features including microretrognathia, hypotelorism, shortening of 
upper arms and legs, and muscular hypertrophy (Figure 1E). Subject 4 was born at 
term: weight 1.400kg (<3rd centile), length 37cm (<3rd centile), head circumference 
27.5cm (<3rd centile). She had a cleft palate, and feeding difficulties that required 
nutritional support until the age of 2 years. She started walking at 2 years of age with 
ataxia, and she does not speak yet. Her brain MRI showed microcephaly, delayed white 
mater myelination in T2 weight images, and mild cerebellar atrophy (Figure S1C). 
Exome sequencing was performed for Subject 1 as well as her unaffected 
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biological parents. The G-band karyotype and SNP array results were normal. Exome 
capture was performed with Agilent SureSelect XT Human All Exon V5 (Agilent, Santa 
Clara, Calif., USA), and 100-bp or 126-bp paired-end read sequencing was performed 
by HiSeq 2500 (Illumina, San Diego, Calif., USA). The sequenced reads were aligned to 
the human genome hg19 using BWA v0.7.12 with BWA-MEM algorithm and ‘-M’ option1. 
The Genome Analysis Toolkit (GATK) v3.3.0 was used for variant discovery2. After 
marking duplicates, local realignment around indels, and base quality score 
recalibration, SNVs and indels for each sample were called using the HaplotypeCaller. 
SNVs and indels with a GQ score above 15 were used for further analysis. The effects 
of variants were predicted by SnpEff v3.6b3 and annotated by ANNOVAR4. Information 
and statistics regarding sequenced reads, mapping rate, and coverage are summarized 
in Table S1. Six de novo mutations in 4 genes (ARCN1, DCAF15, HLA-DRB5, 
FAM58A) were identified. However, variants in DCAF15, HLA-DRB5, and FAM58A 
were present in dbSNP, leaving ARCN1 as the prime candidate gene to account for the 
subject’s phenotype. The mutation in ARCN1 resulted in a premature stop codon in 
exon 2 (NM_001655:exon2:c. 260C>A:p.Ser87*). The ARCN1 mutation was confirmed 
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by Sanger sequencing (Figure 2A and Figure S2A). Sanger sequencing demonstrated 
that the DCAF15 variant was inherited from her unaffected father and the FAM58A 
variants were inherited from her unaffected parents (Figure S3A and S3B). 
Subject 2 was independently identified in a cohort of individuals from 
Singapore with undiagnosed genetic diseases. He had been previously tested and his 
karyotype and chromosome microarray analysis results were normal. Exome 
sequencing of Subject 2 and his unaffected parents was carried out by the Genome 
Institute of Singapore using the NimbleGen SeqCap EZ Human exome V3 kit (Roche, 
Basel Switzerland) and sequenced on the HiSeq 2000 platform (Illumina, San Diego, 
USA) using 100-bp paired-end reads. Alignment to the human genome hg19 was 
carried out using BWA 0.7.5a and the variants were annotated using ANNOVAR. 
Variants with minor allele frequency (MAF) >0.01 in dbSNP or EVS (Exome Variant 
Server) were excluded and rare functional variants were prioritized according to de 
novo status, homozygosity, compound heterozygosity and X chromosome-linkage. 
After filtration, de novo heterozygous variants were identified in ARCN1 and SYT1. Both 
of these variants were confirmed by Sanger sequencing. The ARCN1 mutation was a 
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frameshift variant: NM_001655:c.633del; p.Val212Trpfs*15 predicted to create a 
frameshift in exon 4 starting at codon Val212 and ending in a stop codon 14 positions 
downstream (Figure 2A and Figure S2B). The SYT1 (NM_001135805.1:c.697G>A; 
p.Asp233Asn) variant is a missense variant that substitutes Aspartic acid at codon 233 
with Asparagine (Figure S3C). There were no other potentially pathogenic mutations. 
Subjects 3 and 4 were also ascertained independently. Whole-exome 
sequencing was performed for Subject 3 and his healthy parents by IntegraGen 
Genomics. Exons of DNA samples were captured using an in-solution enrichment 
methodology (Agilent SureSelect All Exon V4 + UTRs) and sequenced with an Illumina 
HiSeq 2000 instrument. SNPs and indels were determined using the CASAVA 1.8 
software. Identification of the disease-causing variants was performed with the Exome 
Resequencing Intelligent Sorter (ERIS, Integragen) program for the annotation and 
filtering of genetic variants. The following criteria were used for excluding 
non-pathogenic variants: (1) variants represented with an allele frequency of more than 
0.5% in dbSNP 138, the NHLBI Exome Sequencing Project EVS, or the in-house 
database of Integragen; (2) variants in the 5’ or 3’ UTR; (3) variants with intronic 
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locations and no prediction of local splice effect; and (4) synonymous variants without 
prediction of local splice effect. Filtered variants occuring de novo were retained for 
further confirmation and segregation analysis by Sanger sequencing. The ARCN1 
mutation was the only probably damaging mutation that occurred de novo in Subject 3 
and was transmitted to his affected daughter, Subject 4. The ARCN1 mutation was 
NM_001655:c.157_158del, leading to p.Ser53Cysfs*39 (Figure S2C). 
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Supplementary Figures  
Figure S1. Additional clinical information of the individuals with ARCN1 mutations. (A) 
Growth chart of Subject 1. Green dots represent height measurements, red dots 
represent weight measurements, and blue dots represent head circumference 
measurements. (B) Radiograph of Subject 2 demonstrating the presence of 
micrognathia. (C) Brain MRI of Subject 4. Microcephaly with gyral simplification, thin 
corpus callosum, delayed myelination and mild cerebellar atrophy are demonstrated. 
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Figure S2. Sanger sequencing chromatogram of ARCN1 mutations. (A) ARCN1 
mutation in Subject 1. Neither of the parents carried the same mutation. (B) ARCN1 
mutation in Subject 2. Neither of the parents carried the same mutation. (C) ARCN1 
mutation in Subjects 3 and 4. ARCN1 mutation was not detected in the parents of 
Subject 3. (D) ARCN1 mutations introduced by CRISPR/Cas9 in HCT116 cell line 
clones. 
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Figure S3. Sanger sequencing confirmation of FAM58A, DCAF15 and SYT1 variants. 
(A) The FAM58A variant was identified not only in Subject 1, but also in both parents, 
arguing against a possible role of the FAM58A variant in explaining the clinical 
phenotype of Subject 1. This variant was reported in dbSNP as rs200645137, and its 
population frequency is between 0.987 and 1.0 in the Human Genetic Variation 
database (http://www.genome.med.kyoto-u.ac.jp/SnpDB/index.html). (B) The DCAF15 
variant was confirmed in Subject 1, but the same variant was also identified in her father, 
arguing against its causality. A similar insertion was reported in dbSNP as rs3217681, 
and its population frequency is 0.407 according to the Human Genetic Variation 
database. (C) The SYT1 variant in Subject 2 was confirmed by Sanger sequencing, and 
neither parent was found to have this variant. This SYT1 variant represents a novel 
variant, and has not been previously reported in the public SNV database.  
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Figure S4.Quantitative RT-PCR and western blot using ARCN1-related syndrome 
subject-derived skin fibroblast samples. (A) Quantitative RT-PCR. Total RNA was 
extracted from fibroblasts with the RNeasy Mini Kit according to the manufacturer’s 
instructions (Qiagen, Courtaboeuf, France). Total RNA was subjected to reverse 
transcription using the iScript cDNA synthesis kit (Bio-rad, Marnes la Coquette, France). 
qPCR was performed in duplicate for each sample using the SybrGreen Supermix 
(Bio-rad). The relative expression of ARCN1 was expressed relative to the expression 
of HPRT. The ARCN1 expression level was significantly reduced in samples from 
Subjects 3 and 4 compared to that of the control sample. *** P<0.001, one-way ANOVA 
followed by a Bonferroni post-test. Two replicates were performed. (B) and (C) ARCN1 
and BiP western blotting. Whole cell extracts were fractionated by SDS-PAGE and 
transferred to a polyvinylidene difluoride (PVDF) membrane. After incubation with 10% 
nonfat milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 1 h, 
membranes were incubated with antibodies against ARCN1 (COP1D, AV54594, 
Sigma-Aldrich), BiP (Grp78, ab21685, Abcam) or beta-Actin (MAB1501, Millipore) 
overnight at 4 °C. Membranes were washed three times and incubated with horseradish 
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peroxidase-conjugated anti-mouse or anti-rabbit antibodies. Blots were washed with 
TBST and developed with the ECL system (Amersham Biosciences) according to the 
manufacturer's protocols. (B) The protein level of ARCN1 was slightly reduced in the 
Subject 4 sample, compared to that of the control sample. Two replicates demonstrated 
consistent results. (C) Western blotting with BiP antibody yielded two bands, and lower 
band representing BiP based on the molecular size (about 78kDa). The BiP protein, 
which is an ER stress marker, was elevated in the Subject 4 sample, compared to that 
of the control.  
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Figure S5. Immunocytochemical analysis. Cultures were fixed for 20 min with 4% 
paraformaldehyde. For immunocytochemistry, the cells were permeabilized with 0.3% 
TritonX-100 for 15min, washed, blocked for 1 h with 10% serum in PBS and incubated 
with primary antibody overnight at 4°C. Primary antibodies used were 
anti-ARCN1/COP1D (ab96725, Abcam), anti-GM130 (610823, BD Transduction Lab), 
anti-GIANTIN (ab80864, Abcam), and anti-PDI (MA3-019, Thermofisher). Following 
washing, cells were treated with secondary antibody for 1 h in the dark at room 
temperature. All images were captured on a Zeiss microscope IMAGER.Z1, using the 
Apotome imaging system coupled to AxioCam MRm and the Axiovision Rel.4.8 
software. BiP represents an ER stress marker, and GIANTIN and GM130 are Golgi 
markers. PDI is a marker of ER. Immunofluorescence staining of the Golgi apparatus 
(GIANTIN and GM130), and that of ER (PDI) as well as COPI vesicle (ARCN1) 
indicated the swollen appearance of the Golgi stacks in the Subject 4’s fibroblast. 
Accumulation of BiP in the cytosol is demonstrated in the Subject 4’s fibroblast 
compared to that of the control.  
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Figure S6. ER stress gene expression was elevated with tunicamycin and thapsigargin 
treatments. Data represents mean ± 2 s.d. *** P<0.001, two-tailed t test; n=3 technical 
replicates per group. Quantitative PCR was run in triplicates, and mean and standard 
deviation was calculated. Two different concentrations of tunicamycin treatment (2µg/ml 
(Tuni2) and 5µg/ml (Tuni5)) and thapsigargin treatment (2µM (Tg2) and 5µM (Tg5)) 
were used. DMSO was added for control. Gene expression level was normalized 
against GAPDH expression. Relative gene expression level to the control sample is 
demonstrated. 
  
